The Pharmaceutical manufacturing company, “Windlas Biotech” has opened its Initial Public Offer (IPO) for subscription from today onwards, that is, from 4th August 2021 in order to raise Rs.401 core. As a matter of fact, this IPO is a mix of fresh issues worth Rs. 165 crore as well well as an offer for sale (OFS) worth Rs. 236.5. Windlas Biotech is one of the topmost companies that offer pharmaceutical formulation contract development and manufacturing organization (CDMO) services to various leading drug companies of India including Pfizer, Cadila and others. Thus, this is a great opportunity for investors who wish to make an investment in the Pharma sector.
Windlas Biotech IPO Share Allotment Status
Windlas Biotech Ltd is one of the prominent pharmaceutical formulations contract development and manufacturing organization in India that offers a wide range of CDMO services including product invention, product formulation, licencing of the products, as well as commercial production of generic and complex products to various drug companies across India. The company was incorporated under the registrar of the company in 2001 and is known for selling their products under their own brand name in both Over counter as well as trade generics markets.
At present, the main objective of the company is to release complex generic products in the chronic therapeutic category linked to lifestyle-related disorders. Moreover, the business operation of the company is expanded in the CDMO products and services, in the domestic as well as OTC market and also outside the country. The company has some major leading drug companies as their clients which include Cadila Healthcare Limited, Pfizer Ltd, Eris Lifesciences Ltd and others. The company has a manufacturing unit at Dehradun having an installed production capacity of 7,063 million capsules, 61.08 million liquid bottles and 54.46 million sachets.
Windlas Biotech Financial’s
AKW WBL Family Private Trust, Ashok Kumar, Hitesh and Manoj Kumar Windlass are the respective promoters of the company. Below mentioned is the financial information for the company for the financial year 2021.
- Total Assets: Rs. 296.12 Cr
- Total Revenue: Rs. 430.69 Cr
- Earnings after tax (EAT): Rs. 15.57 Cr
- P/E ratio: 22.2
- EV/EBITDA ratio: 15.58
The total assets of Widlas Biotech in the company’s balance sheet are recorded to be Rs. 296.12 crores, while the total revenue of the company is recorded to be Rs. 430.69 crores. Meanwhile, the company’s net earning after removing taxes are Rs. 15.57 core, while the price-earnings ratio of the company given by the industry is 22.2. The financial records of the company clearly showcase that the company has a sound balance sheet and in the coming years, the company has a promising future.
Windlas Biotech IPO Details
- Opening Date: 4th August 2021
- Closing Date: 6th August 2021
- Face Value (FV): Rs. 5/equity share
- Price (Fixed): Rs. 448 to Rs. 460/ equity share
- Size of Lot: 30 shares
- Min Order Qty: 30 shares
- Listed: NSE, BSE
- Listing Date (Expected): 17th August 2021
- Issue Type: Book Built Issue
- Issue Size: Rs. 401.54Cr
- Fresh Issue: Rs. 165 Cr (@Rs.5 per share)
- Offer for Sale (OFS) : 51,42,067 Eq Shares @ Rs. 5
- Max. Subscription Lot: 14 lots (420 shares)
The subscription of Windlas Biotech IPO has started on 4th August 2021 and will conclude on 6th August 2021. The offering has an issue size of Rs. 401.54 crore, the face value of which is set at Rs. 5 per equity share. Meanwhile, the company has fixed the price of its IPO from Rs 448 to Rs 460 per equity share. In addition, the maximum subscription lot size of the IPO has been set at 14 or 420 shares and will be listed in the NSE as well as BSE on 17th August 2021. Stay tuned with us.
